Kamada (KMDA) Net Income towards Common Stockholders Growth (3y) (2015 - 2026)
Powered by 
Analysis
Kamada (KMDA) Net Income towards Common Stockholders Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 83.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 83.06% |
| Mar 31, 2026 | 78.38% |
| Dec 31, 2025 | 26.12% |
| Sep 30, 2025 | 148.62% |
| Jun 30, 2025 | 45.07% |
| Mar 31, 2025 | 91.90% |
| Dec 31, 2024 | 30.80% |
| Sep 30, 2024 | 89.18% |
| Jun 30, 2024 | 69.36% |
| Mar 31, 2024 | -2.21% |
| Dec 31, 2023 | 45.23% |
| Sep 30, 2023 | -22.17% |
| Jun 30, 2023 | -19.38% |
| Mar 31, 2023 | -32.89% |
| Dec 31, 2022 | -18.12% |
| Sep 30, 2022 | -56.36% |
| Jun 30, 2022 | -38.18% |
| Mar 31, 2022 | -33.35% |
| Dec 31, 2021 | -31.29% |
| Sep 30, 2021 | 29.30% |